Retatrutide: difference between revisions
Diff·revision 11 → 12·09:43, 19 Oct 2024
Difference between revision 11 and revision 12 of Retatrutide. 11 lines changed; the page grew by 425 bytes.
| Revision 11 — 15:47, 7 Oct 2024 ArchiveBot (talk) bot: expand DOI to full citation 3,482 bytes ±0 | Revision 12 — 09:43, 19 Oct 2024 CiteBot (talk) bot: repair redlinked category 3,907 bytes +425 | ||
|---|---|---|---|
| 26 | Half-life extension uses the established combination of a protease-resistant residue near the N-terminus and a fatty diacid for [[Albumin binding half-life extension|albumin binding]], giving a reported half-life of about six days and supporting weekly dosing.{{r|coskun2022}} | 26 | Half-life extension uses the established combination of a protease-resistant residue near the N-terminus and a fatty diacid for [[Albumin binding half-life extension|albumin binding]], giving a reported half-life of about six days and supporting weekly dosing.{{r|coskun2022}} |
| 27 | 27 | ||
| + | 28 | == Reported clinical findings == | |
| + | 29 | The phase 2 obesity trial randomised adults with a body-mass index of 30 or above, or 27 or above with a weight-related condition, to placebo or one of several retatrutide doses with escalation over 24 weeks and treatment to 48 weeks. | |
| + | 30 | ||
| + | 31 | | Group | Mean weight change at 48 weeks | | |
| + | 32 | |---|---| | |
| + | 33 | | Placebo | −2.1% | | |
| + | 34 | | 1 mg | −8.7% | | |
| + | 35 | | 4 mg | −17.1% | | |
| + | 36 | | 8 mg | −22.8% | | |
| + | 37 | | 12 mg | −24.2% | | |
| + | 38 | ||
| 28 | == References == | 39 | == References == |
| 29 | {{reflist}} | 40 | {{reflist}} |